NO992769D0 - FremgangsmÕte for behandling og forhindring av hjertesvikt og ventricular dilasjon - Google Patents

FremgangsmÕte for behandling og forhindring av hjertesvikt og ventricular dilasjon

Info

Publication number
NO992769D0
NO992769D0 NO992769A NO992769A NO992769D0 NO 992769 D0 NO992769 D0 NO 992769D0 NO 992769 A NO992769 A NO 992769A NO 992769 A NO992769 A NO 992769A NO 992769 D0 NO992769 D0 NO 992769D0
Authority
NO
Norway
Prior art keywords
prevention
procedure
treatment
heart failure
ventricular dilation
Prior art date
Application number
NO992769A
Other languages
English (en)
Other versions
NO992769L (no
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO992769D0 publication Critical patent/NO992769D0/no
Publication of NO992769L publication Critical patent/NO992769L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • External Artificial Organs (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
NO992769A 1996-12-09 1999-06-08 Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon NO992769L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3263196P 1996-12-09 1996-12-09
PCT/US1997/021934 WO1998025597A2 (en) 1996-12-09 1997-12-02 Method for treating and preventing heart failure and ventricular dilatation

Publications (2)

Publication Number Publication Date
NO992769D0 true NO992769D0 (no) 1999-06-08
NO992769L NO992769L (no) 1999-08-09

Family

ID=21865971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992769A NO992769L (no) 1996-12-09 1999-06-08 Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon

Country Status (13)

Country Link
US (1) US5948780A (no)
EP (1) EP1028716A1 (no)
JP (1) JP2001526631A (no)
KR (1) KR20000057444A (no)
AU (1) AU741768B2 (no)
BR (1) BR9714385A (no)
CA (1) CA2263886A1 (no)
IL (1) IL128545A0 (no)
MX (1) MXPA99001974A (no)
NO (1) NO992769L (no)
NZ (1) NZ334897A (no)
WO (1) WO1998025597A2 (no)
ZA (1) ZA9711004B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
HU222986B1 (hu) * 1995-12-22 2004-01-28 Warner-Lambert Co. A mátrix metalloproteinázok működését gátló aromás ketosavak és azok származékai
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
US6624177B1 (en) * 1996-09-04 2003-09-23 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
WO1999047138A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
ES2231708T3 (es) * 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
EP1368323B1 (en) * 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
HU230352B1 (hu) * 2001-06-12 2016-02-29 Wellstat Therapeutics Corporation Metabolikus rendellenességek kezelésére adható vegyületek és ezeket tartalmazó gyógyászati készítmények
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
CA2457033A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. A medecine for cardiac failure
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
BR0312708A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
MXPA05000722A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico carboxilico de la metaloproteinasa-13 de la matriz con un inhibidor selectivo de la ciclooxigenasa-2 que no es celecoxib o valdecoxib.
CA2491820A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB201312311D0 (en) * 2013-07-09 2013-08-21 Uni I Oslo Uses of enzyme inhibitors
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
WO1995029689A1 (en) * 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
AU717570B2 (en) * 1995-06-02 2000-03-30 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
CZ298814B6 (cs) * 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
JP2000511175A (ja) * 1996-05-17 2000-08-29 ワーナー―ランバート・コンパニー ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
IL128545A0 (en) 2000-01-31
NZ334897A (en) 2001-02-23
US5948780A (en) 1999-09-07
KR20000057444A (ko) 2000-09-15
ZA9711004B (en) 1998-10-05
AU5590698A (en) 1998-07-03
CA2263886A1 (en) 1998-06-18
MXPA99001974A (es) 2002-03-27
WO1998025597A3 (en) 2000-10-12
WO1998025597A2 (en) 1998-06-18
EP1028716A1 (en) 2000-08-23
AU741768B2 (en) 2001-12-06
NO992769L (no) 1999-08-09
JP2001526631A (ja) 2001-12-18
BR9714385A (pt) 2000-05-16

Similar Documents

Publication Publication Date Title
NO992769D0 (no) FremgangsmÕte for behandling og forhindring av hjertesvikt og ventricular dilasjon
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
DE69823459D1 (de) Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen
NO923130D0 (no) Behandling av kongestiv hjertesvikt
NO894296L (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
DE69509650D1 (de) Behandlung atrialer fibrillationen
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO991381L (no) Kombinasjonsterapi for behandling av psykoser
NO20014046D0 (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
EP0626174A3 (en) Method and composition for the prophylaxis and / or treatment of underactive organs.
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO893240L (no) Anvendelse av alfa-aminoborsyrederivater til profylaktisk og behandling av virussykdommer.
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO984432L (no) FremgangsmÕte for behandling av migrenesmerte
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
NO934311L (no) alfa,omega-diarylalkanderivater, deres fremstilling og anvendelse ved behandling av sirkulasjonssykdommer og psykoser
AU7854094A (en) Use of amiodarone for the treatment of heart failure
BR9709546A (pt) Formulação e método para tratamento de insuficiéncia cardíaca digestiva
DK0670721T3 (da) Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme
NO892506D0 (no) Kloning og ekspresjon av human vevsfaktor.
NO964291D0 (no) Fremgangsmåte for behandling av allergisk rinitt
NO984190D0 (no) Fremgangsmåte for behandling av insomnia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application